SCHEMBL15543992

SCHEMBL15543992

O=C(COc1ccc(C(Cc2ccccc2)=NOCc2ccccc2)cc1)N1CCOCC1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
SMN1; SMN2 Q16637 3/20 0.53
USP2 O75604 2/20 0.53
GAA P10253 1/20 0.53
FKBP1A P62942 7/20 0.53
HPGD P15428 3/20 0.53
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.53
POLB P06746 1/20 0.52
CYP2C9 P11712 1/20 0.52
GPR183 P32249 3/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
KEAP1 Q14145 2/20 0.50
NFE2L2 Q16236 2/20 0.50
ACHE P22303 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15543990 1.00 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2USP2GAAFKBP1A
SCHEMBL16468221 0.94 FKBP1A (0.57) ALDH1A1SMN1; SMN2USP2GAAFKBP1A
SCHEMBL15561016 0.94 FKBP1A (0.60) ALDH1A1SMN1; SMN2USP2GAAFKBP1A
SCHEMBL15560633 0.94 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2USP2GAAFKBP1A
SCHEMBL15560634 0.94 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2USP2GAAFKBP1A
SCHEMBL15561014 0.94 FKBP1A (0.60) ALDH1A1SMN1; SMN2USP2GAAFKBP1A
SCHEMBL15543994 0.94 FKBP1A (0.60) ALDH1A1SMN1; SMN2FKBP1AHPGDKDM4E
SCHEMBL15543996 0.94 FKBP1A (0.60) ALDH1A1SMN1; SMN2FKBP1AHPGDKDM4E
SCHEMBL16468222 0.94 FKBP1A (0.57) ALDH1A1SMN1; SMN2USP2GAAFKBP1A
SCHEMBL15543208 0.92 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2USP2GAAFKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2864309-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES Cadila Healthcare Limited (IN) 2015-04-29 EP claimed
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LTD (IN) 2015-02-19 US claimed
WO-2014002105-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LIMITED (IN) 2014-01-03 WO claimed
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LTD (IN) 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES PCSK9, HMGCR, CETP ALDH1A1 1508/4885SMN1; SMN2 2595/4885USP2 3924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.